TYNETTA BEAMON-SIMPSON: Open Payments
NPI 1003530098 · BOLIVAR, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$416 in 19 payments from 10 companies in 2025. Trend: 2023 $387 · 2024 $838 · 2025 $416
Food & beverage: $416
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 4 | $98 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
| ABBVIE INC. | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: ARISTADA, INVEGA SUSTENNA, REXULTI, INGREZZA, CAPLYTA, VRAYLAR, UZEDY, ABILIFY ASIMTUFII.
Industry payments across TN — which companies pay providers there.
